PUBLISHER: Allied Market Research | PRODUCT CODE: 1298242
PUBLISHER: Allied Market Research | PRODUCT CODE: 1298242
The skin antiseptic market valued for $1,484.28 million in 2021 and is estimated to reach $3,060.81 million by 2031, exhibiting a CAGR of 7.5% from 2022 to 2031. Skin antiseptics are products or substances that are used to disinfect and clean the skin to reduce the risk of infection. These products are typically used before medical procedures, such as surgery, or injections, or when treating wounds, burns, or other skin conditions. Skin antiseptics work by killing or inhibiting the growth of microorganisms on the skin surface, including bacteria, viruses, and fungi. In addition, they help to remove dirt, oil, and other debris from the skin, which can further reduce the risk of infection. The common skin antiseptics include alcohol-based solutions, such as ethanol or isopropyl alcohol, chlorhexidine, povidone-iodine, and hydrogen peroxide. These products may be applied to the skin using a swab, spray, or other applicator. The choice of antiseptic depends on the specific needs of the patient, the type of procedure being performed, and other factors such as the patient's allergies or sensitivities.
The major factor that drives the growth of skin antiseptic market is increase in number of patients affected by hospital acquired infections (HAIs). For instance, a report of World Health Organization (WHO) 2021, stated that, up to 30% of patients are affected by at least one hospital acquired infections (HAIs) in intensive care units. Thus, rise in prevalence of hospital acquired infections (HAIs) is expected to drive the growth of market. In addition, healthcare facilities have increasingly adopted infection prevention and control guidelines, which include the use of skin antiseptics, thereby driving the market growth.
Furthermore, many key players have adopted key strategies such as partnership, agreement, and expansion to increase their market presence in the global skin antiseptic market, which is expected to drive the growth of the market. For instance, in 2022, PDI Healthcare announced a strategic partnership with the Association for Professionals in Infection Control and Epidemiology (APIC) for advancing the science and practice of infection prevention and control in healthcare facilities, thus such partnerships drive the growth of market.
Furthermore, rise in initiatives by non-government & government organizations to increase awareness about the infection control measures among the patients through different programs and campaigns is anticipated to boost the growth of the market.
However, factor such as side effects associated with certain skin antiseptic restrains the growth of skin antiseptic market. In addition, permeability issue and allergic reactions associated with skin antiseptic hampers the growth of skin antiseptic market.
On the other hand, rise in demand of skin antiseptics for treating infections, increase in government regulations for infection control, and rise in regulatory approvals for skin antiseptic products are expected to offer lucrative opportunities to key players of market.
The skin antiseptic market is segmented into type, form, distribution channel, and region. On the basis of type, the market is categorized into alcohol, chlorhexidine, iodine, and others. On the basis of form, the market is classified into solutions, cream, swab sticks, and others. On the basis of distribution channel, the market is segregated into hospital pharmacies, online providers, and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global skin antiseptic market are: Cardinal Health Inc., Becton, Dickinson and Company, B. Braun SE, 3M Company, Ecolab, Molnlycke Health Care AB, Xttrium Laboratories, SIRMAXO CHEMICALS PVT.LTD., Schulke & Mayr GmbH, and PDI, Inc.